Drugs / TA-HPV
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06315257 | Jul 2025 → Jun 2029 expected | cervical cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
| Phase 1 | NCT00788164 | Nov 2008 → Aug 2023 | cervical cancer, dysplasia of cervix, human papilloma virus infection | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05799144 | Jul 2023 → Sep 2027 expected | oropharyngeal carcinoma | Michael K. Gibson | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06508138 Comparator | Oct 2023 → Apr 2027 expected | human papilloma virus infection, human papillomavirus-related squamous cell carcinoma, metastatic malignant neoplasm | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Enrolling by invitation | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TA-HPV | “Treatment dose: Arm A: pBI-11 DNA (3 mg) twice via intramuscular (IM) injection, followed by one dose of TA-HPV (2.5x10\^5 pfu) via skin inoculation” NCT06315257 ↗3“TA-HPV is an investigational recombinant vaccina virus derived from a strain of the vaccina virus which was widely used for smallpox vaccination.” NCT05799144 ↗ |
| Modality | Vaccine | “HPVE6/E7 recombinant vaccinia vaccine (TA-HPV)” PMID 26420854 ↗ Sep 2015 |
| Route | Intramuscular | “Given intramuscularly” NCT00788164 ↗ |